Cantor Fitzgerald Issues Positive Outlook for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a research report issued on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($3.16) for the year, up from their prior forecast of ($3.46). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Other equities analysts have also issued research reports about the company. Guggenheim restated a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Trading Down 5.6 %

Shares of Dianthus Therapeutics stock opened at $20.74 on Monday. The firm has a market cap of $613.84 million, a P/E ratio of -8.30 and a beta of 1.82. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77. The stock’s fifty day moving average price is $22.34 and its 200-day moving average price is $24.70.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company’s stock worth $96,776,000 after acquiring an additional 36,133 shares in the last quarter. Octagon Capital Advisors LP raised its position in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after acquiring an additional 363,500 shares in the last quarter. TCG Crossover Management LLC purchased a new position in Dianthus Therapeutics during the fourth quarter valued at approximately $32,735,000. Braidwell LP increased its position in shares of Dianthus Therapeutics by 144.4% in the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after buying an additional 712,902 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Dianthus Therapeutics by 13.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock valued at $25,283,000 after buying an additional 136,633 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.